Astera Labs, Inc. (ALAB)
Official siteTECHNOLOGY • SEMICONDUCTORS • NASDAQ
Market Cap: $38.77B
Last updated: Nov 17, 2026 at 11:05 AM ET
Astera Labs, Inc. (ALAB) Stock Forecast
Analysts expect Astera Labs (ALAB) to earn $4.38 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.03B. Of 26 analysts, 18 rate the stock Buy or Strong Buy, 8 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 26 ratings average 2.04, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 69% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 7 | 26.9% |
| Buy | 11 | 42.3% |
| Hold | 8 | 30.8% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 26
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 63.2% and revenue estimates rise 67.0%.
- Fiscal year ending Dec 31, 2026
- $4.38
- EPS consensus, revenue $2.03B
- Fiscal year ending Dec 31, 2027
- $7.15
- EPS consensus, revenue $3.39B
- Next report
- Feb 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $4.38 | $4.34 to $4.48 | 23 | $2.03B | $2.02B to $2.05B | 22 |
| Dec 31, 2027 | $7.15 | $4.45 to $9.02 | 24 | $3.39B | $2.25B to $4.02B | 24 |
Quarterly Estimates
The EPS consensus falls from $1.68 for the quarter ending Dec 31, 2026 to $1.67 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.68 | $1.59 to $1.82 | 24 | $754.72M | $685.61M to $803.25M | 23 |
| Mar 31, 2027 | $1.67 | $1.55 to $1.97 | 20 | $776.51M | $746.00M to $824.00M | 17 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 5 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 8.4% from $4.04.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $4.38 | $4.06 | $4.04 | $4.04 | $4.04 | +8.5% |
| Fiscal year ending Dec 31, 2027 | $7.15 | $6.52 | $6.39 | $6.39 | $6.39 | +11.9% |
| Quarter ending Mar 31, 2027 | $1.67 | $1.46 | $1.46 | $1.46 | $1.46 | +14.2% |
Frequently Asked Questions About ALAB
What is the ALAB stock forecast?
Consensus analyst estimates put Astera Labs's EPS at $4.38 for the fiscal year ending Dec 31, 2026, on revenue of $2.03B. The consensus rating from 26 analysts is Buy.
How do analysts rate ALAB stock?
Of 26 analysts covering Astera Labs, 7 rate it Strong Buy, 11 Buy, 8 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ALAB next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $4.38, with estimates from $4.34 to $4.48 from 23 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $7.15, with estimates from $4.45 to $9.02 from 24 analysts.
What revenue do analysts expect from Astera Labs next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.03B, with estimates from $2.02B to $2.05B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $3.39B, with estimates from $2.25B to $4.02B.
How many analysts cover ALAB?
26 analysts rate Astera Labs stock, and 23 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ALAB pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors